114 related articles for article (PubMed ID: 35115086)
1. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.
Coniglio AC; Segar MW; Loungani RS; Savla JJ; Grodin JL; Fox ER; Garg S; de Lemos JA; Berry JD; Drazner MH; Shah S; Hall ME; Shah A; Khan SS; Mentz RJ; Pandey A
JACC Heart Fail; 2022 Feb; 10(2):129-138. PubMed ID: 35115086
[TBL] [Abstract][Full Text] [Related]
2. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population.
Greve AM; Christoffersen M; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
JAMA Cardiol; 2021 Mar; 6(3):258-266. PubMed ID: 33237279
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Burden of the V142I Transthyretin Variant.
Selvaraj S; Claggett B; Shah SH; Mentz RJ; Khouri MG; Manichaikul AW; Khan SS; Rich SS; Mosley TH; Levitan EB; Arora P; Goyal P; Haring B; Eaton CB; Cheng RK; Wells GL; Manson JE; Fontana M; Solomon SD
JAMA; 2024 Jun; 331(21):1824-1833. PubMed ID: 38734952
[TBL] [Abstract][Full Text] [Related]
4. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.
Parcha V; Malla G; Irvin MR; Armstrong ND; Judd SE; Lange LA; Maurer MS; Levitan EB; Goyal P; Arora G; Arora P
JAMA; 2022 Apr; 327(14):1368-1378. PubMed ID: 35377943
[TBL] [Abstract][Full Text] [Related]
5. Can We Manage Presymptomatic TTR V142I Related Risk?
Murray MF; Miller EJ
JACC Heart Fail; 2022 Feb; 10(2):139-141. PubMed ID: 35115087
[No Abstract] [Full Text] [Related]
6. Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults.
Saha A; Patel KV; Ayers C; Ballantyne CM; Correa A; Defilippi C; Hall ME; Mentz RJ; Seliger SL; Yimer W; Butler J; Berry JD; De Lemos JA; Pandey A
J Card Fail; 2023 Jan; 29(1):6-15. PubMed ID: 35690315
[TBL] [Abstract][Full Text] [Related]
7. Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Sinha A; Zheng Y; Nannini D; Qu Y; Hou L; Shah SJ; Yancy CW; McNally EM; Fornage M; Lima J; Lloyd-Jones DM; Rasmussen-Torvik LJ; Khan SS
JAMA Cardiol; 2020 Dec; 6(6):1-5. PubMed ID: 33355618
[TBL] [Abstract][Full Text] [Related]
8. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
9. The amyloidogenic V122I transthyretin variant in elderly black Americans.
Quarta CC; Buxbaum JN; Shah AM; Falk RH; Claggett B; Kitzman DW; Mosley TH; Butler KR; Boerwinkle E; Solomon SD
N Engl J Med; 2015 Jan; 372(1):21-9. PubMed ID: 25551524
[TBL] [Abstract][Full Text] [Related]
10. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
Haring B; Hunt RP; Shadyab AH; Eaton C; Kaplan R; Martin LW; Panjrath G; Kuller LH; Assimes T; Kooperberg C; Wassertheil-Smoller S
JACC Heart Fail; 2023 Sep; 11(9):1189-1199. PubMed ID: 36930136
[TBL] [Abstract][Full Text] [Related]
12. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
[TBL] [Abstract][Full Text] [Related]
13. Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults.
Patel KV; Simek S; Ayers C; Neeland IJ; deFilippi C; Seliger SL; Lonergan K; Minniefield N; Mentz RJ; Correa A; Yimer WK; Hall ME; Rodriguez CJ; de Lemos JA; Berry JD; Pandey A
JACC Heart Fail; 2021 Jul; 9(7):484-493. PubMed ID: 34119468
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
Kozlitina J; Garg S; Drazner MH; Matulevicius SA; Ayers C; Overton J; Reid J; Baras A; Rao K; Pandey A; Berry J; de Lemos JA; Grodin JL
J Card Fail; 2022 Mar; 28(3):403-414. PubMed ID: 34634447
[TBL] [Abstract][Full Text] [Related]
15. Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study.
Pandey A; Keshvani N; Ayers C; Correa A; Drazner MH; Lewis A; Rodriguez CJ; Hall ME; Fox ER; Mentz RJ; deFilippi C; Seliger SL; Ballantyne CM; Neeland IJ; de Lemos JA; Berry JD
JAMA Cardiol; 2019 Jan; 4(1):51-58. PubMed ID: 30566191
[TBL] [Abstract][Full Text] [Related]
16. Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of
Kaniper S; Lynch D; Owens SM; Ibric L; Vabishchevich Y; Nyantakyi N; Chun F; Sam L; Fabrizio C; Hamad E; Gerhard GS
J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38541013
[TBL] [Abstract][Full Text] [Related]
17. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
[TBL] [Abstract][Full Text] [Related]
18. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.
Rosenblum H; Castano A; Alvarez J; Goldsmith J; Helmke S; Maurer MS
Circ Heart Fail; 2018 Apr; 11(4):e004769. PubMed ID: 29615436
[TBL] [Abstract][Full Text] [Related]
19. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis.
Hamour IM; Lachmann HJ; Goodman HJ; Petrou M; Burke MM; Hawkins PN; Banner NR
Am J Transplant; 2008 May; 8(5):1056-9. PubMed ID: 18318779
[TBL] [Abstract][Full Text] [Related]
20. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
Thenappan T; Fedson S; Rich J; Murks C; Husain A; Pogoriler J; Anderson AS
Amyloid; 2014 Jun; 21(2):120-3. PubMed ID: 24818650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
